Randomised controlled trialindependent cross-checkabstract checked I-CHM-118 standard review
Breaking down tumour stroma did not help patients live longer
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.
Overview
Van Cutsem E et al.. J Clin Oncol 2020 · PMID 32706635 · DOI 10.1200/JCO.20.00590
A drug that degrades pancreatic tumour stroma, added to chemotherapy, did not prolong survival (11.2 vs 11.5 months).
Does the study support the specific claim? No · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Test stroma-degrading drug in patients
- How was the study done?
Randomised blinded trial
- How many people, animals or samples were studied?
494 patients
- What was actually found?
No survival gain
- How large was the observed effect?
HR 1.00
- What do the results mean in everyday life?
The fibrosis explanation for treatment failure did not hold up in patients
- What are the study's limitations?
One drug, one cancer
- What does it say about Elawady's specific claim?
Contradicts the claim's mechanism
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Does not rule out other stroma roles
Scientific in-depth review
1. Full reference
- Authors
- Van Cutsem E et al.
- Journal
- J Clin Oncol
- Year
- 2020
- Identifier
- PMID 32706635 DOI 10.1200/JCO.20.00590
- Verification
- verified – PubMed efetch 2026-10-26 (PublicationType and CommentsCorrections checked); Crossref 2026-10-26
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
Not stated in abstract (PubMed lists NIH grants and non-US-government support).
2. Research question
Does stroma-degrading PEGPH20 added to chemotherapy improve survival in hyaluronan-high metastatic pancreatic cancer?
3. Study design and population
- Study design
- Randomised controlled trial – Randomised double-blind placebo-controlled phase III trial (HALO 109-301)
- Population
Adults with untreated metastatic hyaluronan-high PDA
- Country
International
- Period
Not stated in abstract
- Sample size
494 randomised (492 ITT)
- Inclusion and exclusion criteria
Hyaluronan-high metastatic PDA
4. Methods and endpoints
- Exposure / intervention
PEGPH20 plus nab-paclitaxel/gemcitabine
- Comparator
Placebo plus nab-paclitaxel/gemcitabine
- Endpoints
OS (primary), PFS, ORR, safety
- Statistical methods
HRs; ORR ratio
5. Actual results
- Results
Median OS 11.2 vs 11.5 months (HR 1.00, 0.80-1.27; P=.97); PFS 7.1 vs 7.1 months (HR 0.97, 0.75-1.26); ORR 47% vs 36% (ratio 1.29, 1.03-1.63); more grade >=3 fatigue, muscle spasms, hyponatraemia.
- Absolute risks
No survival difference
- Authors' conclusion
Adding PEGPH20 increased response rate but did not improve OS or PFS; further development not supported.
6. Strengths
- Large double-blind RCT
- Biomarker-selected
7. Weaknesses
- Metastatic setting only
- Sponsor details not read (abstract only)
8. Risk of bias
- Orienting tool
- RoB 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
Double-blind randomised.
9. Assessment of the statistical interpretation
HR 1.00 (0.80-1.27) log-symmetric (stats/C-CHM-11.py).
10. Relevance to the specific claim
Tests the stroma hypothesis directly in humans: degrading a stromal component did not improve survival. Chemotherapy was still the active backbone in both arms.
11. Independent contrary findings
Preclinical stroma-resistance data (I-CHM-11, I-CHM-119).
12. Transferability to Germany and Europe
Applicable.
13. Overall methodological judgement
High-quality negative test of a stroma-targeting strategy.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | low |
| Precision of results | high |
| Directness | indirect |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Other stroma-targeting approaches.
15. Linked fact checks
- Cancer cells resist chemotherapy because of their fibrotic interstitial (stromal) environment; fibrosis strangles cells, which then turn cancerous and resist chemo and radiation. – Studies contradicting or limiting the claim